Your browser doesn't support javascript.
loading
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata, Sandro; Oza, Amit; Hall, Geoff; Pardo, Beatriz; Madry, Radoslaw; Cibula, David; Klat, Jaroslav; Montes, Ana; Glasspool, Rosalind; Colombo, Nicoletta; Pete, Imre; Herrero Ibáñez, Ana; Marín, Margarita Romeo; Ilieva, Rumyana; Timcheva, Constanta; Di Maio, Massimo; Blakeley, Christopher; Taylor, Rosie; Barnicle, Alan; Clamp, Andrew.
Afiliação
  • Pignata S; Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, Italy. Electronic address: s.pignata@istitutotumori.na.it.
  • Oza A; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Hall G; St James's University Hospital, Leeds, UK.
  • Pardo B; ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Madry R; Medical University Karol Marcinkowski, Poznan, Poland.
  • Cibula D; General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Klat J; University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Montes A; Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Glasspool R; Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK.
  • Colombo N; University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy.
  • Pete I; National Institute of Cancer, Budapest, Hungary.
  • Herrero Ibáñez A; Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Marín MR; ICO Badalona - Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
  • Ilieva R; MHAT 'Central Onco Hospital', OOD, Plovdiv, Bulgaria.
  • Timcheva C; MHAT for Women's Health - Nadezhda, OOD, Sofia, Bulgaria.
  • Di Maio M; Department of Oncology, University of Turin, At Mauriziano Hospital, Turin, Italy.
  • Blakeley C; AstraZeneca, Cambridge, UK.
  • Taylor R; AstraZeneca, Cambridge, UK.
  • Barnicle A; AstraZeneca, Cambridge, UK.
  • Clamp A; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
Gynecol Oncol ; 172: 121-129, 2023 05.
Article em En | MEDLINE | ID: mdl-37030280
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antineoplásicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Antineoplásicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2023 Tipo de documento: Article